These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30044795)

  • 1. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing.
    Hellwig S; Nix DA; Gligorich KM; O'Shea JM; Thomas A; Fuertes CL; Bhetariya PJ; Marth GT; Bronner MP; Underhill HR
    PLoS One; 2018; 13(7):e0197333. PubMed ID: 30044795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
    Lampignano R; Neumann MHD; Weber S; Kloten V; Herdean A; Voss T; Groelz D; Babayan A; Tibbesma M; Schlumpberger M; Chemi F; Rothwell DG; Wikman H; Galizzi JP; Riise Bergheim I; Russnes H; Mussolin B; Bonin S; Voigt C; Musa H; Pinzani P; Lianidou E; Brady G; Speicher MR; Pantel K; Betsou F; Schuuring E; Kubista M; Ammerlaan W; Sprenger-Haussels M; Schlange T; Heitzer E
    Clin Chem; 2020 Jan; 66(1):149-160. PubMed ID: 31628139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
    Underhill HR
    Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of DNA lesions associated with cell-free DNA by targeted deep sequencing.
    Shin SH; Park WY; Park D
    BMC Med Genomics; 2021 Jul; 14(1):192. PubMed ID: 34320984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA.
    Frydendahl A; Rasmussen MH; Jensen SØ; Henriksen TV; Demuth C; Diekema M; Ditzel HJ; Wen SWC; Pedersen JS; Dyrskjøt L; Andersen CL
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
    Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
    Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.
    Shi X; Duose DY; Mehrotra M; Harmon MA; Hu P; Wistuba II; Kopetz S; Luthra R
    Cancer Genet; 2019 Sep; 237():82-89. PubMed ID: 31447070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis.
    Till JE; Black TA; Gentile C; Abdalla A; Wang Z; Sangha HK; Roth JJ; Sussman R; Yee SS; O'Hara MH; Thompson JC; Aggarwal C; Hwang WT; Elenitoba-Johnson KSJ; Carpenter EL
    J Mol Diagn; 2021 Nov; 23(11):1545-1552. PubMed ID: 34454115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
    Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
    Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA.
    Zvereva M; Roberti G; Durand G; Voegele C; Nguyen MD; Delhomme TM; Chopard P; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Brennan P; Foll M; Byrnes GB; McKay JD; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2020 May; 55():102462. PubMed ID: 32249202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.
    Pandoh PK; Corbett RD; McDonald H; Alcaide M; Kirk H; Trinh E; Haile S; MacLeod T; Smailus D; Bilobram S; Mungall AJ; Ma Y; Moore RA; Coope R; Zhao Y; Jones SJ; Holt RA; Karsan A; Morin RD; Marra MA
    Biotechniques; 2019 Feb; 66(2):85-92. PubMed ID: 30744412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling.
    van der Leest P; Ketelaar EM; van Noesel CJM; van den Broek D; van Boerdonk RAA; Deiman B; Rifaela N; van der Geize R; Huijsmans CJJ; Speel EJM; Geerlings MJ; van Schaik RHN; Jansen MPHM; Dane-Vogelaar R; Driehuis E; Leers MPG; Sidorenkov G; Tamminga M; van Kempen LC; Schuuring E
    Clin Chem; 2022 Jul; 68(7):963-972. PubMed ID: 35616097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Single-Nucleotide Polymorphism-Based Fetal Fraction Estimation of Maternal Plasma Circulating Cell-Free DNA Using Bayesian Hierarchical Models.
    Larson NB; Wang C; Na J; Rowsey RA; Highsmith WE; Hoppman NL; Kocher JP; Klee EW
    J Comput Biol; 2018 Sep; 25(9):1040-1049. PubMed ID: 29932737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection.
    Maruzani R; Brierley L; Jorgensen A; Fowler A
    BMC Genomics; 2024 Sep; 25(1):827. PubMed ID: 39227777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
    Leest PV; Janning M; Rifaela N; Azpurua MLA; Kropidlowski J; Loges S; Lozano N; Sartori A; Irwin D; Lamy PJ; Hiltermann TJN; Groen HJM; Pantel K; Kempen LCV; Wikman H; Schuuring E
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 19. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.
    van Dessel LF; Vitale SR; Helmijr JCA; Wilting SM; van der Vlugt-Daane M; Oomen-de Hoop E; Sleijfer S; Martens JWM; Jansen MPHM; Lolkema MP
    Mol Oncol; 2019 Feb; 13(2):392-402. PubMed ID: 30516338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.